Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Atara Biotherapeutics, Inc. (ATRA : NSDQ)
 
 • Company Description   
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.

Number of Employees: 153

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.47 Daily Weekly Monthly
20 Day Moving Average: 39,245 shares
Shares Outstanding: 5.96 (millions)
Market Capitalization: $50.46 (millions)
Beta: 0.18
52 Week High: $18.71
52 Week Low: $5.01
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.53% -4.91%
12 Week 59.72% 33.99%
Year To Date -36.40% -40.43%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1280 RANCHO CONEJO BLVD
-
THOUSAND OAKS,CA 91320
USA
ph: 805-623-4211
fax: -
achapman@atarabio.com http://www.atarabio.com
 
 • General Corporate Information   
Officers
AnhCo Thieu Nguyen - President; Chief Executive Officer and Director
Pascal Touchon - Chairman and Director
Eric Hyllengren - Chief Financial Officer and Chief Operating Office
Carol G. Gallagher - Director
Matthew K. Fust - Director

Peer Information
Atara Biotherapeutics, Inc. (CORR.)
Atara Biotherapeutics, Inc. (RSPI)
Atara Biotherapeutics, Inc. (CGXP)
Atara Biotherapeutics, Inc. (BGEN)
Atara Biotherapeutics, Inc. (GTBP)
Atara Biotherapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 046513206
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/11/25
Share - Related Items
Shares Outstanding: 5.96
Most Recent Split Date: 6.00 (0.04:1)
Beta: 0.18
Market Capitalization: $50.46 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.50 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 0.25
EPS Growth
vs. Year Ago Period: 160.87%
vs. Previous Quarter: 394.12%
Sales Growth
vs. Year Ago Period: 258.77%
vs. Previous Quarter: 199.66%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -14.51
12/31/24 - -63.93
Current Ratio
06/30/25 - -
03/31/25 - 0.57
12/31/24 - 0.48
Quick Ratio
06/30/25 - -
03/31/25 - 0.57
12/31/24 - 0.40
Operating Margin
06/30/25 - -
03/31/25 - -7.83
12/31/24 - -66.24
Net Margin
06/30/25 - -
03/31/25 - -7.83
12/31/24 - -66.24
Pre-Tax Margin
06/30/25 - -
03/31/25 - -7.85
12/31/24 - -66.24
Book Value
06/30/25 - -
03/31/25 - -9.24
12/31/24 - -16.89
Inventory Turnover
06/30/25 - -
03/31/25 - 3.64
12/31/24 - 1.41
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©